Latest news
Otsuka’s Voyxact raises the bar in IgA nephropathy - biocentury.combiocentury.com · Fri, 07 Aug 2026 22:14:00 GMTOtsuka's VOYXACT hits VISIONARY two-year eGFR goal in IgA nephropathy - DealroomDealroom · Wed, 05 Aug 2026 04:43:21 GMTOtsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial - YahooYahoo · Tue, 04 Aug 2026 15:19:30 GMTSibeprenlimab (Voyxact) Stabilizes Kidney Function in IgAN - HCPLiveHCPLive · Tue, 04 Aug 2026 15:04:13 GMTOtsuka reports VOYXACT phase 3 eGFR gain in IgA nephropathy - International Business TimesInternational Business Times · Tue, 04 Aug 2026 14:43:23 GMTOtsuka Unveils Phase 3 VOYXACT Results for IgA Nephropathy Treatment - World Business OutlookWorld Business Outlook · Tue, 04 Aug 2026 05:40:13 GMTOtsuka's Voyxact Halts Kidney Function Decline In Phase 3 IgAN Trial, Strengthening FDA Approval Bid - londoninsider.co.uklondoninsider.co.uk · Mon, 03 Aug 2026 23:18:29 GMTOtsuka’s VOYXACT Phase 3 Data Show Sustained Kidney Function Stabilization in IgA Nephropathy - TipRanksTipRanks · Mon, 03 Aug 2026 21:56:51 GMT